Drug Combination Details
| General Information of the Combination (ID: C72207) | |||||
|---|---|---|---|---|---|
| Name | Pterostilbene NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G1 phase | ||||
| In-vitro Model | NCI-N87 | CVCL_1603 | Gastric tubular adenocarcinoma | Homo sapiens | ||
| MKN45 | CVCL_0434 | Gastric adenocarcinoma | Homo sapiens | |||
| In-vivo Model | N87 cells (3 * 105 cells) were suspended in 0.1 mL of PBS and then inoculated subcutaneously into the right flank of five-week-old male BALB/c nude mice. | |||||
| Experimental
Result(s) |
Pterostilbene enhances sorafenib's anticancer effects on gastric adenocarcinoma. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-N87 | CVCL_1603 | Gastric tubular adenocarcinoma | Homo sapiens | ||
| MKN45 | CVCL_0434 | Gastric adenocarcinoma | Homo sapiens | |||
| In-vivo Model | N87 cells (3*105 cells) were suspended in 0.1 mL of PBS and inoculated subcutaneously into the right flank of five-week-old male BALB/c nude mice. | |||||
| Experimental
Result(s) |
PET enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Pterostilbene enhances sorafenib's anticancer effects on gastric adenocarcinoma. J Cell Mol Med. 2020 Nov;24(21):12525-12536. | |||
